<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427517</url>
  </required_header>
  <id_info>
    <org_study_id>6721</org_study_id>
    <secondary_id>U54NS065768</secondary_id>
    <nct_id>NCT01427517</nct_id>
  </id_info>
  <brief_title>Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease</brief_title>
  <official_title>Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are interested in determining if the investigators are able to detect
      changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with
      Parkinson's disease (PD), those with Gaucher's disease (GD), and those without neurological
      disorders (healthy controls) when they are given the antioxidant N-acetylcysteine (NAC).
      This study will combine information from a medical history, a physical examination and
      disease rating scales with results obtained using MRS brain scans and pharmacokinetic
      studies from blood samples. This research will require 1 visit that will require about 4 to
      5 hours of time. During this study, participants will provide their medical history, be
      examined and undergo a rating scale for about one hour; the brain scan and pharmacokinetic
      studies will require 1.5-2 hours of time; in total the study will take about 4-5 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxidative stress is implicated in the pathogenesis of a number of neurodegenerative diseases
      such as Parkinson's disease (PD). Further, levels of glutathione (GSH), a prevalent
      endogenous antioxidant, are decreased in the postmortem substantia nigra (SN) of individuals
      with PD, indicating increased oxidative stress, although this has yet not been confirmed in
      vivo. Increases in intracellular oxidative stress have also been observed in primary
      fibroblast cultures obtained from patients with GD, where enzyme replacement therapy
      resulted in increases in total GSH. The hypothesis that oxidative stress plays a key role in
      the neurodegeneration associated with PD suggests that antioxidants may be useful in
      altering disease progression.

      N-acetylcysteine (NAC) is a well-known antioxidant that is thought to act both as a free
      radical scavenger and as a cysteine donor for the synthesis of GSH. NAC may be beneficial in
      the treatment of PD and GD. Magnetic resonance spectroscopy (MRS) methods may be able to
      determine if there are effects from NAC on central nervous system GSH levels. In addition,
      use of red blood cell (RBC) measurements of GSH, if correlated with brain concentrations,
      could serve as an easily measured biomarker to help characterize and monitor response to
      therapy. The investigators therefore propose to conduct a study of the effect of a single,
      intravenous dose of NAC on central (brain) measures of GSH and peripheral (RBC) measures of
      GSH in people with PD and healthy controls, through the use of simultaneous MRS techniques
      and pharmacokinetic studies. The investigators hypothesis and specific aims are as follows:

      Hypothesis: RBC and brain GSH concentrations will increase following oral NAC administration
      in individuals with Parkinson's disease (PD), Gaucher's disease (GD), and control
      participants.

      Specific Aims:

        1. Quantitate baseline plasma and red blood cell GSH concentrations in those with PD and
           GD and controls; and characterize NAC and GSH pharmacokinetics after a single
           intravenous NAC administration.

        2. Quantitate brain GSH levels (as ascertained through MRS) in those with PD and GD and
           controls at baseline and after a single intravenous NAC administration simultaneously
           with Aim 1.

        3. Construct a pharmacokinetic model to evaluate the relationship between peripheral
           (plasma and RBC) and central (brain) GSH measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Brain GSH</measure>
    <time_frame>Baseline and up to 110 minutes post-NAC administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in brain GSH levels from baseline to post-NAC administration (90 - 110 minutes) in all subjects</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Gaucher's Disease</condition>
  <arm_group>
    <arm_group_label>NAC in PD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous administration of N-acetylcysteine in PD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAC in GD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous administration of N-acetylcysteine in GD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAC in controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous administration of N-acetylcysteine in control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Single, intravenous administration of N-acetylcysteine</description>
    <arm_group_label>NAC in PD</arm_group_label>
    <arm_group_label>NAC in GD</arm_group_label>
    <arm_group_label>NAC in controls</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All participants must be 18 years or older.

          2. All enrollees must understand and cooperate with requirements of the study in the
             opinion of the investigators and must be able to provide written informed consent.

          3. Individuals with medically stable Parkinson's disease (in the opinion of the
             investigator).

          4. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or
             vitamin E for 3 weeks prior to the study.

          5. Absence of dementia in all subjects, as determined by pre-scanning cognitive
             assessment.

          6. Control subjects who are able to undergo MRS

        Exclusion Criteria:

          1. Inability to undergo MRI scanning without sedation

          2. Medically unstable conditions in any group as determined by the investigators

          3. Pregnant or lactating or those women of child-bearing age that are not using
             acceptable forms of contraception

          4. Diagnosis of asthma that is presently being treated with ANY medication, or past
             history of asthma/bronchospasm resulting in an emergency room visit, hospitalization
             or treatment

          5. Unable to adhere to study protocol for whatever reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Tuite, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rarediseasesnetwork.epi.usf.edu/</url>
    <description>Rare Disease Clinical Research Network</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2011</firstreceived_date>
  <firstreceived_results_date>May 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Gaucher's disease</keyword>
  <keyword>Control</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gaucher Disease</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were primarily recruited from the investigators' clinics at the University of Minnesota, and from research volunteers signed up with the University's Center for Magnetic Resonance Research.</recruitment_details>
      <pre_assignment_details>Groups were not assigned in this study. All subjects received the same intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NAC in PD</title>
          <description>single intravenous administration of N-acetylcysteine in PD patients</description>
        </group>
        <group group_id="P2">
          <title>NAC in GD</title>
          <description>single intravenous administration of N-acetylcysteine in GD patients</description>
        </group>
        <group group_id="P3">
          <title>NAC in Controls</title>
          <description>single intravenous administration of N-acetylcysteine in control subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NAC in PD</title>
          <description>single intravenous administration of N-acetylcysteine in PD patients</description>
        </group>
        <group group_id="B2">
          <title>NAC in GD</title>
          <description>single intravenous administration of N-acetylcysteine in GD patients</description>
        </group>
        <group group_id="B3">
          <title>NAC in Controls</title>
          <description>single intravenous administration of N-acetylcysteine in control subjects</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.33" spread="3.21"/>
                <measurement group_id="B2" value="44" spread="23.58"/>
                <measurement group_id="B3" value="58" spread="0"/>
                <measurement group_id="B4" value="52.11" spread="13.46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brain GSH</title>
        <description>change in brain GSH levels from baseline to post-NAC administration (90 - 110 minutes) in all subjects</description>
        <time_frame>Baseline and up to 110 minutes post-NAC administration</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC in PD</title>
            <description>single intravenous administration of N-acetylcysteine in PD patients</description>
          </group>
          <group group_id="O2">
            <title>NAC in GD</title>
            <description>single intravenous administration of N-acetylcysteine in GD patients</description>
          </group>
          <group group_id="O3">
            <title>NAC in Controls</title>
            <description>single intravenous administration of N-acetylcysteine in control subjects</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Brain GSH</title>
            <description>change in brain GSH levels from baseline to post-NAC administration (90 - 110 minutes) in all subjects</description>
            <units>percent increase from baseline</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55" spread="24.4"/>
                  <measurement group_id="O2" value="41" spread="16.3"/>
                  <measurement group_id="O3" value="34" spread="19.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NAC in PD</title>
          <description>single intravenous administration of N-acetylcysteine in PD patients</description>
        </group>
        <group group_id="E2">
          <title>NAC in GD</title>
          <description>single intravenous administration of N-acetylcysteine in GD patients</description>
        </group>
        <group group_id="E3">
          <title>NAC in Controls</title>
          <description>single intravenous administration of N-acetylcysteine in control subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <description>Following scan, a subject complained of itchy of hands, nasal congestion, sore throat. Study staff noted swelling around eyes and flushed cheeks &amp; neck. Subject was taken to ER (not admitted)&amp; received standard treatment for allergic reaction to NAC.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Holmay</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-812-5854</phone>
      <email>holma101@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
